There is one clinical trial.
To evaluate the efficacy and safety of azvudine in treatment of COVID-19
Description: (reduction) in viral load from baseline
Measure: Change (reduction) in viral load from baseline Time: On day 7 and 14Description: proportion of subjects change from mild or moderate type to severe type
Measure: proportion of subjects change from mild or moderate type to severe type Time: up to 21 daysDescription: proportion of subjects change from severe type to critical type
Measure: proportion of subjects change from severe type to critical type Time: up to 21 daysDescription: novel coronavirus nucleic acid conversion rate
Measure: novel coronavirus nucleic acid conversion rate Time: up to 21 daysDescription: Novel coronavirus nucleic acid negative conversion time
Measure: Novel coronavirus nucleic acid negative conversion time Time: up to 21 daysDescription: TIme(Days);Proportion(percent)
Measure: The time and proportion of improvement in pulmonary imaging Time: up to 21 daysDescription: TIme(Days);Proportion(percent)
Measure: Time and proportion of temperature return to normal Time: up to 21 daysDescription: TIme(Days);Proportion(percent)
Measure: time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.) Time: up to 21 daysDescription: TIme(Days);Proportion(percent)
Measure: time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms Time: up to 21 daysDescription: Changes of blood oxygen detection index
Measure: Changes of blood oxygen detection index Time: up to 21 daysDescription: Frequency of requirement for supplemental oxygen or non-invasive ventilation
Measure: Frequency of requirement for supplemental oxygen or non-invasive ventilation Time: up to 21 daysDescription: Frequency of adverse events
Measure: Frequency of adverse events Time: up to 21 days